Autism spectrum disorders: An historical synthesis and a multidimensional assessment toward a tailored therapeutic program / Jean XAVIER in Research in Autism Spectrum Disorders, 18 (October 2015)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 18 (October 2015) . - p.21-33 Titre : Autism spectrum disorders: An historical synthesis and a multidimensional assessment toward a tailored therapeutic program Type de document : Texte imprimé et/ou numérique Auteurs : Jean XAVIER, Auteur ; Claude BURSZTEJN, Auteur ; Maitri STISKIN, Auteur ; Roberto CANITANO, Auteur ; David COHEN, Auteur Article en page(s) : p.21-33 Langues : Anglais (eng) Mots-clés : Categorical  Developmental  Multidimensional assessment  Integrative perspective  Tailored therapeutic proposal Index. décimale : PER Périodiques Résumé : Abstract Autism is a large group of disorders. From the first description in 1943 until know, attempts to propose nosological boundaries, through successive redefinitions of diagnostic criteria, have not succeeded in constraining the extensiveness nor in explaining the heterogeneity of autism. The failure of the categorical approach is revealed by several indices, including excessive comorbidity, the frequent use of Not Otherwise Specified categories and diagnostic uncertainty in borderline cases. Several proposals have been formulated to categorize subgroups of children with complex severe developmental disorders but less severe trajectories than typical autism. The diversity and overlap in their clinical expression emphasize the importance of using a multidimensional assessment inscribed in a developmental perspective. In this way, clinicians could encompass the issues of the categorical approach, address the child holistically and then achieve a functional diagnosis enabling the elaboration of a tailored therapeutic proposal. En ligne : http://dx.doi.org/10.1016/j.rasd.2015.06.011 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=268 [article] Autism spectrum disorders: An historical synthesis and a multidimensional assessment toward a tailored therapeutic program [Texte imprimé et/ou numérique] / Jean XAVIER, Auteur ; Claude BURSZTEJN, Auteur ; Maitri STISKIN, Auteur ; Roberto CANITANO, Auteur ; David COHEN, Auteur . - p.21-33. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 18 (October 2015) . - p.21-33 Mots-clés : Categorical  Developmental  Multidimensional assessment  Integrative perspective  Tailored therapeutic proposal Index. décimale : PER Périodiques Résumé : Abstract Autism is a large group of disorders. From the first description in 1943 until know, attempts to propose nosological boundaries, through successive redefinitions of diagnostic criteria, have not succeeded in constraining the extensiveness nor in explaining the heterogeneity of autism. The failure of the categorical approach is revealed by several indices, including excessive comorbidity, the frequent use of Not Otherwise Specified categories and diagnostic uncertainty in borderline cases. Several proposals have been formulated to categorize subgroups of children with complex severe developmental disorders but less severe trajectories than typical autism. The diversity and overlap in their clinical expression emphasize the importance of using a multidimensional assessment inscribed in a developmental perspective. In this way, clinicians could encompass the issues of the categorical approach, address the child holistically and then achieve a functional diagnosis enabling the elaboration of a tailored therapeutic proposal. En ligne : http://dx.doi.org/10.1016/j.rasd.2015.06.011 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=268

Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy / Aine RODDY ; Martin KNAPP ; Celso ARANGO ; Maria Andreina MENDEZ ; James CUSACK ; Declan MURPHY ; Roberto CANITANO ; Bethany OAKLEY ; Vinciane QUOIDBACH in Journal of Autism and Developmental Disorders, 54-7 (July 2024)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 54-7 (July 2024) . - p.2733-2741 Titre : Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy Type de document : Texte imprimé et/ou numérique Auteurs : Aine RODDY, Auteur ; Martin KNAPP, Auteur ; Celso ARANGO, Auteur ; Maria Andreina MENDEZ, Auteur ; James CUSACK, Auteur ; Declan MURPHY, Auteur ; Roberto CANITANO, Auteur ; Bethany OAKLEY, Auteur ; Vinciane QUOIDBACH, Auteur Article en page(s) : p.2733-2741 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children?s families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For England and Spain, oxcarbazepine is the most cost-effective treatment when taken as additional treatment for those children whose response to monotherapy is suboptimal. In Ireland and Italy, gabapentin is the most cost-effective option. Our additional scenario analysis presents the aggregate cost to families with autistic children who are being treated for epilepsy: this cost is considerably higher than healthcare provider expenditure. En ligne : https://doi.org/10.1007/s10803-023-05941-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=533 [article] Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy [Texte imprimé et/ou numérique] / Aine RODDY, Auteur ; Martin KNAPP, Auteur ; Celso ARANGO, Auteur ; Maria Andreina MENDEZ, Auteur ; James CUSACK, Auteur ; Declan MURPHY, Auteur ; Roberto CANITANO, Auteur ; Bethany OAKLEY, Auteur ; Vinciane QUOIDBACH, Auteur . - p.2733-2741. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 54-7 (July 2024) . - p.2733-2741 Index. décimale : PER Périodiques Résumé : We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children?s families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For England and Spain, oxcarbazepine is the most cost-effective treatment when taken as additional treatment for those children whose response to monotherapy is suboptimal. In Ireland and Italy, gabapentin is the most cost-effective option. Our additional scenario analysis presents the aggregate cost to families with autistic children who are being treated for epilepsy: this cost is considerably higher than healthcare provider expenditure. En ligne : https://doi.org/10.1007/s10803-023-05941-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=533

Epilepsy in Autism Spectrum Disorders: Clinical Aspects and Implications for Treatment / Roberto CANITANO

Public ISBD contenu dans New Autism Research Developments / Barbara S. MESMERE Titre : Epilepsy in Autism Spectrum Disorders: Clinical Aspects and Implications for Treatment Type de document : Texte imprimé et/ou numérique Auteurs : Roberto CANITANO, Auteur ; Valeria SCANDURRA, Auteur Année de publication : 2008 Importance : p.197-209 Langues : Anglais (eng) Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=670 contenu dans New Autism Research Developments / Barbara S. MESMERE Epilepsy in Autism Spectrum Disorders: Clinical Aspects and Implications for Treatment [Texte imprimé et/ou numérique] / Roberto CANITANO, Auteur ; Valeria SCANDURRA, Auteur . - 2008 . - p.197-209. Langues : Anglais (eng) Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=670

Exemplaires

Code-barres	Cote	Support	Localisation	Section	Disponibilité
aucun exemplaire

Evaluating Sex and Age Differences in ADI-R and ADOS Scores in a Large European Multi-site Sample of Individuals with Autism Spectrum Disorder / J. TILLMANN in Journal of Autism and Developmental Disorders, 48-7 (July 2018)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 48-7 (July 2018) . - p.2490-2505 Titre : Evaluating Sex and Age Differences in ADI-R and ADOS Scores in a Large European Multi-site Sample of Individuals with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : J. TILLMANN, Auteur ; K. ASHWOOD, Auteur ; M. ABSOUD, Auteur ; Sven BÖLTE, Auteur ; Frédérique BONNET-BRILHAULT, Auteur ; Jan K. BUITELAAR, Auteur ; Sara CALDERONI, Auteur ; R. CALVO, Auteur ; Ricardo CANAL-BEDIA, Auteur ; Roberto CANITANO, Auteur ; Annelies A. DE BILDT, Auteur ; Marie GOMOT, Auteur ; P. J. HOEKSTRA, Auteur ; A. KAALE, Auteur ; H. MCCONACHIE, Auteur ; D. G. MURPHY, Auteur ; A. NARZISI, Auteur ; I. OOSTERLING, Auteur ; M. PEJOVIC-MILOVANCEVIC, Auteur ; A. M. PERSICO, Auteur ; O. PUIG, Auteur ; H. ROEYERS, Auteur ; Nanda N. ROMMELSE, Auteur ; R. SACCO, Auteur ; V. SCANDURRA, Auteur ; A. C. STANFIELD, Auteur ; E. ZANDER, Auteur ; Tony CHARMAN, Auteur Article en page(s) : p.2490-2505 Langues : Anglais (eng) Mots-clés : Age  Autism Spectrum Disorder  Phenotype  Sex  Symptom severity Index. décimale : PER Périodiques Résumé : Research on sex-related differences in Autism Spectrum Disorder (ASD) has been impeded by small samples. We pooled 28 datasets from 18 sites across nine European countries to examine sex differences in the ASD phenotype on the ADI-R (376 females, 1763 males) and ADOS (233 females, 1187 males). On the ADI-R, early childhood restricted and repetitive behaviours were lower in females than males, alongside comparable levels of social interaction and communication difficulties in females and males. Current ADI-R and ADOS scores showed no sex differences for ASD severity. There were lower socio-communicative symptoms in older compared to younger individuals. This large European ASD sample adds to the literature on sex and age variations of ASD symptomatology. En ligne : http://dx.doi.org/10.1007/s10803-018-3510-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=367 [article] Evaluating Sex and Age Differences in ADI-R and ADOS Scores in a Large European Multi-site Sample of Individuals with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / J. TILLMANN, Auteur ; K. ASHWOOD, Auteur ; M. ABSOUD, Auteur ; Sven BÖLTE, Auteur ; Frédérique BONNET-BRILHAULT, Auteur ; Jan K. BUITELAAR, Auteur ; Sara CALDERONI, Auteur ; R. CALVO, Auteur ; Ricardo CANAL-BEDIA, Auteur ; Roberto CANITANO, Auteur ; Annelies A. DE BILDT, Auteur ; Marie GOMOT, Auteur ; P. J. HOEKSTRA, Auteur ; A. KAALE, Auteur ; H. MCCONACHIE, Auteur ; D. G. MURPHY, Auteur ; A. NARZISI, Auteur ; I. OOSTERLING, Auteur ; M. PEJOVIC-MILOVANCEVIC, Auteur ; A. M. PERSICO, Auteur ; O. PUIG, Auteur ; H. ROEYERS, Auteur ; Nanda N. ROMMELSE, Auteur ; R. SACCO, Auteur ; V. SCANDURRA, Auteur ; A. C. STANFIELD, Auteur ; E. ZANDER, Auteur ; Tony CHARMAN, Auteur . - p.2490-2505. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 48-7 (July 2018) . - p.2490-2505 Mots-clés : Age  Autism Spectrum Disorder  Phenotype  Sex  Symptom severity Index. décimale : PER Périodiques Résumé : Research on sex-related differences in Autism Spectrum Disorder (ASD) has been impeded by small samples. We pooled 28 datasets from 18 sites across nine European countries to examine sex differences in the ASD phenotype on the ADI-R (376 females, 1763 males) and ADOS (233 females, 1187 males). On the ADI-R, early childhood restricted and repetitive behaviours were lower in females than males, alongside comparable levels of social interaction and communication difficulties in females and males. Current ADI-R and ADOS scores showed no sex differences for ASD severity. There were lower socio-communicative symptoms in older compared to younger individuals. This large European ASD sample adds to the literature on sex and age variations of ASD symptomatology. En ligne : http://dx.doi.org/10.1007/s10803-018-3510-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=367

Glutamatergic agents in Autism Spectrum Disorders: Current trends / Roberto CANITANO in Research in Autism Spectrum Disorders, 8-3 (March 2014)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 8-3 (March 2014) . - p.255-265 Titre : Glutamatergic agents in Autism Spectrum Disorders: Current trends Type de document : Texte imprimé et/ou numérique Auteurs : Roberto CANITANO, Auteur ; Valeria SCANDURRA, Auteur Article en page(s) : p.255-265 Langues : Anglais (eng) Mots-clés : Glutamate  Autism Spectrum Disorders  Novel treatments  Childhood and adolescence Index. décimale : PER Périodiques Résumé : Abstract Glutamate transmission dysfunction has been found in various preclinical models of Autism Spectrum Disorders (ASD), thus the glutamate system is a target for therapeutics. This report reviews current treatments for glutamate dysfunction in ASD models and clinical trials. Antagonists of metabotropic glutamate receptor subtype 5 (mGluR5) have been tested in preclinical models of autism. Black and Tan Bachyuric (BTBR) mice model behavioral phenotypes of the three core diagnostic domains of autism, e.g. social deficits, impaired language and communication, and repetitive behaviors. A significant reduction in repetitive self-grooming was observed after mGluR5 antagonist administration in BTBR mice. SHANK 3 deficient mice which have altered synaptic transmission and plasticity, were administered IGF-1 treatment to reverse these deficits based on the hypothesis that reduced AMPA receptor levels reflect less mature synapses. Clinical trials have been carried out in ASD with glutamate NMDA receptors, but current findings are not sufficient for conclusions on safety and efficacy. Memantine is an NMDA antagonist under investigation in controlled trials that hopefully will provide new insight on its use in autism. Studies using novel treatments with other glutamatergic agents are also underway and encouraging results have been observed with N-acetylcysteine in treating irritability in ASD. En ligne : http://dx.doi.org/10.1016/j.rasd.2013.12.009 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=224 [article] Glutamatergic agents in Autism Spectrum Disorders: Current trends [Texte imprimé et/ou numérique] / Roberto CANITANO, Auteur ; Valeria SCANDURRA, Auteur . - p.255-265. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 8-3 (March 2014) . - p.255-265 Mots-clés : Glutamate  Autism Spectrum Disorders  Novel treatments  Childhood and adolescence Index. décimale : PER Périodiques Résumé : Abstract Glutamate transmission dysfunction has been found in various preclinical models of Autism Spectrum Disorders (ASD), thus the glutamate system is a target for therapeutics. This report reviews current treatments for glutamate dysfunction in ASD models and clinical trials. Antagonists of metabotropic glutamate receptor subtype 5 (mGluR5) have been tested in preclinical models of autism. Black and Tan Bachyuric (BTBR) mice model behavioral phenotypes of the three core diagnostic domains of autism, e.g. social deficits, impaired language and communication, and repetitive behaviors. A significant reduction in repetitive self-grooming was observed after mGluR5 antagonist administration in BTBR mice. SHANK 3 deficient mice which have altered synaptic transmission and plasticity, were administered IGF-1 treatment to reverse these deficits based on the hypothesis that reduced AMPA receptor levels reflect less mature synapses. Clinical trials have been carried out in ASD with glutamate NMDA receptors, but current findings are not sufficient for conclusions on safety and efficacy. Memantine is an NMDA antagonist under investigation in controlled trials that hopefully will provide new insight on its use in autism. Studies using novel treatments with other glutamatergic agents are also underway and encouraging results have been observed with N-acetylcysteine in treating irritability in ASD. En ligne : http://dx.doi.org/10.1016/j.rasd.2013.12.009 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=224

Identification of a Novel Pathogenic Variant in the NAGLU Gene in a Child with Neurodevelopmental Delay / Lucia Pia BRUNO in Journal of Autism and Developmental Disorders, 52-10 (October 2022)  

Permalink

Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency / Latha V. SOORYA in Molecular Autism, (June 2013)  

Permalink

Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects / David COHEN in Research in Autism Spectrum Disorders, 7-1 (January 2013)  

Permalink

Tics and Tourette syndrome in autism spectrum disorders / Roberto CANITANO in Autism, 11-1 (January 2007)  

Permalink

---

1 (1 - 9 / 9)